Table 2.

Prevalence, period prevalence, incidence and persistence of HPV DNA by HPV type and multiplicity of infection in Mexican soldiers

TypeBaseline cohort (n = 1,030)
Follow-up cohort (n = 336)
No. who acquired infection/no. at risk (%)*No. whom infection persisted/no. at risk (%)*
SingleMultipleTotal (%)SingleMultipleTotal (%)
HPV negative571165
HPV positive226233456 (44.6)8586171 (50.9)45/210 (21.4)37/126 (29.4)
Oncogenic135211358 (34.8)5181132 (39.3)32/210 (15.2)31/100 (31.0)
Nononcogenic§91185246 (23.9)34539 (11.6)13/210 (6.19)6/26 (23.1)
HPV positive
Oncogenic
    16144862 (6.0)42125 (7.4)55/16
    18142438 (3.7)01414 (4.2)10/9
    3171522 (2.1)2810 (3.0)10/6
    33077 (0.7)000 (0.0)00
    35347 (0.7)101 (0.3)00/1
    39103545 (4.4)51217 (5.1)33/12
    4592635 (3.4)41317 (5.1)22/13
    51213657 (5.5)81624 (7.1)54/14
    52154661 (5.9)92332 (9.5)86/17
    53173855 (5.3)41014 (4.2)12/10
    5651621 (2.0)2911 (3.3)01/7
    5893645 (4.4)71320 (6.0)43/12
    59236891 (8.8)62632 (9.5)410/25
    6852428 (2.7)41216 (4.8)21/11
    7301313 (1.3)112 (0.6)00/2
    82066 (0.6)113 (0.9)30
Nononcogenic
    6103444 (4.3)21618 (5.4)61/9
    11122335 (3.4)51116 (4.8)30/9
    26189 (0.9)134 (1.2)20/2
    4001313 (1.3)033 (0.9)00/1
    42279 (0.9)235 (1.5)30/2
    5453540 (3.9)189 (2.7)10/8
    5572128 (2.7)246 (1.8)11/5
    57000 (0.0)000 (0.0)00
    6682836 (3.5)61319 (5.7)50/8
    8393036 (3.5)21113 (3.9)23/11
    84235376 (7.1)121527 (8.0)38/23
Total2296949199126635862
  • * 210 individuals were HPV negative at baseline and at risk for acquiring the infection, and persistence was defined as having the same HPV type at both samplings.

  • Percentage of the total study population.

  • For the follow-up cohort, defined as having a high-risk type at baseline or follow-up.

  • § In follow-up study, defined as having a low-risk type at baseline or follow-up.